# A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

> **NCT07189949** · PHASE1 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Solid Tumors Harboring RAS Mutations or Amplifications

## Interventions

- **DRUG:** HRS-2329 Tablet

## Key facts

- **NCT ID:** NCT07189949
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-16
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07189949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07189949, "A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07189949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*